Safety and Efficacy of Losmapimod in Non-ST-Segment Elevation Acute Myocardial Infarction - SOLSTICE


Losmapimod is a novel p38 mitogen-activated protein kinase (MAPK) inhibitor that has been shown in preclinical studies to improve vascular function, reduce plaque inflammation, and reduce infarct size. The current trial is a phase II trial that sought to study the safety and efficacy of losmapimod in patients with non–ST-segment elevation myocardial infarction (NSTEMI).